HDCN Abstract:  ASN Annual Meeting -- San Francisco  

Oreopoulos DG, Bargman JM, Fang W

ACE Inhibitors/ARB and Survival in Patients on Peritoneal Dialysis.

ASN Annual Meeting -- San Francisco
J Am Soc Nephrol (Nov) 18:708A 2007

Objective: Angiotensin-converting enzyme (ACE) inhibitors have been shown to improve outcome in patients with renal failure not on dialysis therapy and patients on hemodialysis (HD). However, their effect on survival has not been studied in peritoneal dialysis (PD) patients. The present study examined the association between therapy with ACE inhibitor/ ARB and mortality in patients undergoing chronic PD.

Methods: All patients who commenced PD between January 1, 2000, and December 31, 2005 at the University Health Network were included. Patients were grouped according to whether they had been treated with ACE inhibitor/ARB. They were followed up from the date of PD initiation until death, cessation of PD, transfer to other centers or to the end of the study (December 31, 2006).

Results: A total of 306 patients were included in the study. 165 were treated with ACE inhibitors/ARB (treated group) and 141 had not (untreated group). The treated group were younger (56.916.6 vs 62.317.8 years, p<0.01) and had higher blood pressure (systolic: 138.821.8 vs 128.622.4 mmHg, diastolic: 79.814.1 vs 74.512.5, both p<0.01) at the initiation of PD. The treated group had a significantly longer survival compared to the untreated group (Log Rank 19.191, p<0.001). After adjusting for age, blood pressure and other demographic and clinical parameters, multivariable Cox proportional hazards modeling showed that use of ACE inhibitor/ARB was associated with 60% reduced risk for death (HR 0.397, 95%CI 0.241-0.653, p<0.001).

Conclusion: In this retrospective analysis, ACE inhibitor/ARB therapy was associated with a dramatically reduced mortality in patients on peritoneal dialysis independent of achieved blood pressure and other clinical and demographic variables.

The poster for this abstract is available for viewing. YOU MUST SIGN IN FIRST at the ASN Posters2View website: (you need to type in a separate username and password of your choosing). If you are not signed in, the direct link to the poster below will not work!

Once signed in, you can access the poster for this abstract directly at this link.


Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.